LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis

Author:

Li Kexian1ORCID,Feng Zengyu1,Qin Kai1,Ma Yang1,Zhao Shiwei1,Chen Peng1,Lin Jiewei1,Jiang Yongsheng1,Han Lijie1,Cao Yizhi1,Luo Jiaxin1,Shi Minmin1,Chen Hao1,Wang Jiancheng1,Jiang Lingxi1,Peng ChenghongORCID

Affiliation:

1. Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

Abstract

Abstract Background Pancreatic cancer, of which pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent type, is one of the most malignant tumors, with a 5-year survival rate of about 10%. Pancreatic cancer stem cells play pivotal roles in chemoresistance and recurrence. Long non-coding RNAs (lncRNAs) have been identified as key regulators of the biological progression of various cancers. LncRNAs were found to be associated with cancer stem cells, which are related to chemoresistance. LINC01137 has been reported as an oncogene in oral squamous cell carcinoma, and bioinformatic analysis found it associated with pancreatic cancer stem cells. This study is aim to discover the function and the underlying mechanism of LINC01137 in pancreatic cancer. Results LINC01137 was pancreatic cancer stem cell-associated lincRNA and associated with stem genes. LINC01137 was upregulated in pancreatic cancer tissues and cell lines. Its high expression correlated with poor prognosis. Knockdown of LINC01137 expression reduced pancreatic cancer stemness, chemoresistance, and proliferation. Mechanistically, LINC01137 mostly located in cytoplasm and exerted its biological function by binding to miR-7155-5p to activate the KLF12/PI3K/AKT pathway. KLF12 also promoted LINC01137 expression. LINC01137 and KLF12 were involved in promoting PDAC tumorigenesis. Conclusion Our results suggested that LINC01137 functions as an oncogene in pancreatic cancer and identified its post-transcriptional regulatory mechanisms, which may contribute to targeted therapy for pancreatic cancer.

Publisher

Research Square Platform LLC

Reference44 articles.

1. Pancreatic cancer;Vincent A;Lancet,2011

2. Cancer statistics in China, 2015;Chen W;CA Cancer J Clin,2016

3. Cancer statistics for the US Hispanic/Latino population, 2021;Miller KD;CA Cancer J Clin,2021

4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. 2021. CA Cancer J Clin. 2021; 71(1):7–33.

5. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience;Cloyd JM;J Gastrointest Surg,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3